Project Grant R01CA316494
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $589K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Cancer Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $684,857 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a randomized controlled trial expanding the BRIDGE intervention—a person-centered collaborative care model designed to improve cancer care delivery and outcomes for individuals with serious mental illness. The award funds a five-year project (September 1, 2026 through August 31, 2031)...
- The National Cancer Institute awarded Massachusetts General Hospital $1.611 million on September 12, 2025, under Cancer Treatment Research (CFDA 93.395) to conduct a randomized controlled trial testing the efficacy of SMART3RP-Lymphoma, a virtual, resilience-based group intervention, in improving quality of life and reducing anxiety, depression, and physical symptoms among early post-treatment lymphoma survivors (0–2 years after curative-intent treatment). The study enrolls 254 participants...
- The National Cancer Institute awarded The MGH Institute of Health Professions, Inc. $696,498 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and optimize a multicomponent intervention for improving functional recovery and participation in life roles among breast cancer survivors. The research uses the Multiphase Optimization Strategy (MOST) framework to systematically test three remotely delivered intervention components: priority elicitation to...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $424,256 to The General Hospital Corporation (Massachusetts General Hospital, Research Management Division) on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a computational framework for optimal immune monitoring during cancer treatment. The project constructs compartmental models connecting tissue-level lymphocyte dynamics to blood count data,...
- The National Cancer Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $604,347 under the Cancer Treatment Research program (CFDA 93.395) on July 7, 2026, to conduct a multi-site randomized controlled trial of BREEZE+, a brief behavioral intervention for dyspnea management in patients with advanced lung cancer. BREEZE+ combines two nurse-led intervention sessions, a nurse-led booster session, and a digital health app designed to reinforce dyspnea management...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $747,660 on June 2, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct the RADIANT trial, which builds evidence for a scalable remote patient monitoring and integrative medicine intervention delivered via telemedicine to reduce hospital readmissions in medical oncology patients discharged to home. The trial addresses the 12-week readmission rate for cancer patients, which ranges...
- The National Cancer Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $162,608 under the Cancer Treatment Research program (CFDA 93.395) on August 14, 2026. The award funds an exploratory research project characterizing how moderate-dose external radiotherapy enhances blood perfusion in hepatocellular carcinoma tumors, with the goal of optimizing combination strategies between ionizing radiation and perfusion-driven therapies. The research involves irradiating a...
- The National Cancer Institute awarded Massachusetts General Hospital $225,360 on September 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop and pilot test SLEEPCARE, a multimodal telehealth behavioral intervention designed to reduce sleep disturbance in caregivers of patients with primary malignant brain tumors. The five-year project, running through August 31, 2031, addresses a gap in clinical care: approximately 55 percent of caregivers in this population experience...
- The National Cancer Institute awarded Duke University $668,691 on March 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct a randomized controlled trial testing interventions for older women with breast cancer undergoing adjuvant aromatase inhibitor therapy. The award funds a hierarchical 2×2 factorial trial evaluating two interventions: a clinic and provider-level geriatric oncology assessment linked with support for AI therapy (GOAL-AI), and a patient-level...
- The National Cancer Institute awarded Brigham & Women's Hospital Inc. $756,755 on August 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and test a structured peer support intervention for patients undergoing hematopoietic stem cell transplantation. The award is classified as a Project Grant with a period of performance through July 31, 2031, and place of performance in Boston, Massachusetts. The intervention, called STEPP (Structured Peer Support Intervention),...